Ningbo Comprege Pharmaceutical Technology

Comprege Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Ningbo, China, focused on the discovery and development of novel small molecule therapeutics. The company utilizes a proprietary structure-based drug design (SBDD) platform to create highly selective inhibitors for targets in immunology and oncology. Its lead program, CPG-0527, is a potent and selective TYK2 inhibitor currently in Phase 2 clinical trials for the treatment of moderate-to-severe plaque psoriasis. Beyond dermatology, Comprege is advancing a pipeline of candidates targeting JAK1 and other kinases to treat various autoimmune disorders and solid tumors. The company is backed by prominent venture capital firms and aims to deliver differentiated treatments for global markets.